Article PDF
Avoid common mistakes on your manuscript.
References
Baselga, J., Albanell, J., Ruiz, A., Lluch, A., Gascon, P., Guillem, V., Gonzalez, S., Sauleda, S., Marimon, I., Tabernero, J. M., Koehler, M. T., and Rojo, F. Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer. J. Clin. Oncol., 23, 5323–5333 (2005).
Divella, R., Tommasi, S., Lacalamita, R., Daniele, A., Abbate, I., Garrisi, V. M., Savino, E., Coviello, M., Rubini, V., Simone, G., Paradiso, A., and Quaranta, M., Circulating hTERT DNA in early breast cancer. Anticancer Res., 29, 2845–2849 (2009).
Kang, S. S., Kwon, T., Kwon, D. Y., and Do, S. I. Akt protein kinase enhances human telomerase activity through phosphorylation of telomerase reverse transcriptase subunit. J. Biol. Chem., 274, 13085–13090 (1999).
Moon, D. H., Kim, M. O., Heo, M. S., Lee, J. D., Choi, Y. H., and Kim, G. Y. Gefitinib induces apoptosis and decrease telomerase activity in MDA-MB-231 human breast cancer cells. Arch. Pharm. Res., 32, 1351–1360 (2009).
Nicholson, S., Sainsbury, J. R., Halcrow, P., Chambers, P., Farndon, J. R., and Harris, A. L. Expression of epidermal growth factor receptors associated with lack of response to endocrine therapy in recurrent breast cancer. Lancet, 1, 182–185 (1989).
Penne, K., Bohlin, C., Schneider, S., and Allen, D. Gefitinib (Iressa, ZD1839) and tyrosine kinase inhibitors: the wave of the future in cancer therapy. Cancer Nurs., 28, 481–486 (2005).
Robertson, J. F., Come, S. E., Jones, S. E., Beex, L., Kaufmann, M., Makris, A., Nortier, J. W., Possinger, K., and Rutqvist, L. E. Endocrine treatment options for advanced breast cancer-the role of fulvestrant. Eur. J. Cancer, 41, 346–356 (2005).
Thatcher, N., Chang, A., Parikh, P., Rodrigues Pereira, J., Ciuleanu, T., Von Pawel, J., Thongprasert, S., Tan, E. H., Pemberton, K., Archer, V., and Carroll, K. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet, 366, 1527–1537 (2005).
Von Minckwitz, G., Jonat, W., Fasching, P., Du Bois, A., Kleeberg, U., Luck, H. J., Kettner, E., Hilfrich, J., Eiermann, W., Torode, J., and Schneeweiss, A. A multicentre phase II study on gefitinib in taxane- and anthracycline-pretreated metastatic breast cancer. Breast Cancer Res. Treat, 89, 165–172 (2005).
Wu, K. J., Grandori, C., Amacker, M., Simon-Vermot, N., Polack, A., Lingner, J., and Dalla-Favera, R. Direct activation of TERT transcription by c-MYC. Nat. Genet., 21, 220–224 (1999).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lee, C.H. This month in APR. Arch. Pharm. Res. 32, 1333–1334 (2009). https://doi.org/10.1007/s12272-009-1920-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12272-009-1920-8